METHYLPHENIDATE HYDROCHLORIDE | N021284 | SANDOZ INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from KVK-Tech, Inc. (Abhai, LLC) FDA-2017-P-2496 Abhai, LLC filed this citizen petition requesting the FDA to determine whether Ritalin LA (methylphenidate hydrochloride) Extended-Release Capsules 60 mg, NDA 021284, held by Novartis Pharmaceuticals Corporation, was voluntarily withdrawn from the commercial market for safety or effectiveness reason | 505(q) | 2017-04-20 | Granted | KVK-Tech, Inc. (Abhai, LLC) |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$2.35
per ea
Lowest NADAC/Unit
$1.62
per ea
Brand NDCs
0
Generic NDCs
7
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00781238301METHYLPHENIDATE ER(LA) 10 MG CP | $2.35 | EA | Generic | — | 2026-10-21 |
| 00781238601METHYLPHENIDATE ER(LA) 40 MG CP | $1.77 | EA | Generic | — | 2026-10-21 |
| 00781236401METHYLPHENIDATE ER(LA) 40 MG CP | $1.77 | EA | Generic | — | 2026-10-21 |
| 00781236301METHYLPHENIDATE ER(LA) 30 MG CP | $1.72 | EA | Generic | — | 2026-10-21 |
| 00781238501METHYLPHENIDATE ER(LA) 30 MG CP | $1.72 | EA | Generic | — | 2026-10-21 |
| 00781238401METHYLPHENIDATE ER(LA) 20 MG CP | $1.62 | EA | Generic | — | 2026-10-21 |
| 00781236201METHYLPHENIDATE ER(LA) 20 MG CP | $1.62 | EA | Generic | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.